Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2016

View Archived Issues

Bio-Path completes the safety portion of phase II trial evaluating BP-1001 in AML

TGV Laboratories outlines discovery of MV-4 with antiviral potential

Collaboration to evaluate avelumab in combination with defactinib in ovarian cancer

Syndax prices its initial public offering

Bristol-Myers Squibb patents ROCK2 inhibitors

Tesevatinib receives FDA orphan drug designation for the treatment of ARKPD

Cornell University describes immunoproteasome inhibitors

ContraVir demonstrates safety of FV-100 in drug-drug interaction study

Versitech and State Key Laboratory of Natural Product Chemistry report agents for liver disease

Novel vaccines and blood safety measures to combat global Zika virus outbreak

Rainbow Medical and Medos collaborate to treat spinal degenerative disc disease

PRAME oncogene expression is a prognostic biomarker in uveal melanoma

Hydra Biosciences presents TRPC5 antagonists

Onconova receives notice of termination from Baxalta regarding rigosertib agreement

MediSynergics divulges antiprotozoal compounds

Merck KGaA collaborates with EMBL to study cancer metabolism

Cyclic form of AChE-derived peptide as novel therapeutic approach in Alzheimer's disease

Yuhan Corporation and Sorrento Therapeutics form joint venture company

Ensemble achieves early-stage research milestone in Alexion collaboration

FDA grants orphan drug designation to BHV-0223 for spinocerebellar ataxia

Grunenthal and Axxam collaborate in pain and inflammation

Small molecule GS-5734 protects monkeys from Ebola virus disease

CaM-dependent RyR2 inhibitor shows promise for the treatment of arrhythmias

Phase II trial investigates intraductal administration of fulvestrant in DCIS or breast cancer

Encochleated amikacin receives FDA orphan drug designation for NTM infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...